keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunotherapy

keyword
https://www.readbyqxmd.com/read/28074864/a-novel-monoclonal-antibody-targeting-coxsackie-virus-and-adenovirus-receptor-inhibits-tumor-growth-in-vivo
#1
Manabu Kawada, Hiroyuki Inoue, Masunori Kajikawa, Masahito Sugiura, Shuichi Sakamoto, Sakiko Urano, Chigusa Karasawa, Ihomi Usami, Mitsuru Futakuchi, Tohru Masuda
To create a new anti-tumor antibody, we conducted signal sequence trap by retrovirus-meditated expression method and identified coxsackie virus and adenovirus receptor (CXADR) as an appropriate target. We developed monoclonal antibodies against human CXADR and found that one antibody (6G10A) significantly inhibited the growth of subcutaneous as well as orthotopic xenografts of human prostate cancer cells in vivo. Furthermore, 6G10A also inhibited other cancer xenografts expressing CXADR, such as pancreatic and colorectal cancer cells...
January 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28070824/tolerability-of-an-immunologically-enhanced-subcutaneous-immunotherapy-preparation-in-patients-treated-with-concomitant-allergy-immunotherapy-a-non-interventional-observational-study
#2
Rainer Reiber, Hendrik Wolf, Jörg Schnitker, Eike Wüstenberg
BACKGROUND: For causal treatment by allergy immunotherapy (AIT) a single or few allergen products for the clinically most relevant allergens are applied to treat multiple allergies, but few data on the tolerability of multiple AIT applications are available. OBJECTIVE: The aim of our study was to investigate safety and tolerability in patients treated by subcutaneous immunotherapy (SCIT) and concomitant SCIT or sublingual immunotherapy (SLIT) products. METHODS: In a non-interventional, observational study in Germany treatment of patients with a primary SCIT and concomitant AIT (SCIT or SLIT) was documented during the first 4 months of treatment...
January 9, 2017: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/28065341/allergen-immunotherapy-for-a-teenager-with-seasonal-allergic-rhinitis-due-to-grass-pollen-subcutaneous-or-sublingual-route
#3
REVIEW
Harold S Nelson, Stephen R Durham
No abstract text is available yet for this article.
January 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28063043/subcutaneous-and-sublingual-immunotherapy-in-a-mouse-model-of-allergic-asthma
#4
Laura Hesse, Martijn C Nawijn
Allergic asthma, caused by inhaled allergens such as house dust mite or grass pollen, is characterized by reversible airway obstruction, associated with an eosinophilic inflammation of the airways, as well as airway hyper responsiveness and remodeling. The inhaled allergens trigger a type-2 inflammatory response with involvement of innate lymphoid cells (ILC2) and Th2 cells, resulting in high production of immunoglobulin E (IgE) antibodies. Consequently, renewed allergen exposure results in a classic allergic response with a distinct early and late phase, both resulting in bronchoconstriction and shortness of breath...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28057014/cocktail-treatment-with-egfr-specific-and-cd133-specific-chimeric-antigen-receptor-modified-t-cells-in-a-patient-with-advanced-cholangiocarcinoma
#5
Kai-Chao Feng, Ye-Lei Guo, Yang Liu, Han-Ren Dai, Yao Wang, Hai-Yan Lv, Jian-Hua Huang, Qing-Ming Yang, Wei-Dong Han
BACKGROUND: Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality, and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell (CART) immunotherapy represents a novel strategy for the management of many malignancies. However, the potential of CART therapy in treating advanced unresectable/metastatic CCA is uncharted so far. CASE PRESENTATION: In this case, a 52-year-old female who was diagnosed as advanced unresectable/metastatic CCA and resistant to the following chemotherapy and radiotherapy was treated with CART cocktail immunotherapy, which was composed of successive infusions of CART cells targeting epidermal growth factor receptor (EGFR) and CD133, respectively...
January 5, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28056956/effectiveness-of-regionally-specific-immunotherapy-for-the-management-of-canine-atopic-dermatitis
#6
Jon D Plant, Moni B Neradilek
BACKGROUND: Canine atopic dermatitis is a common pruritic skin disease often treated with allergen immunotherapy (AIT). AIT in dogs traditionally begins with attempting to identify clinically relevant environmental allergens. Current allergen testing methodologies and immunotherapy techniques in dogs are not standardized. Immunotherapy with a mixture of allergenic extracts selected based on regional aerobiology rather than intradermal tests or serum IgE assays has been described. The objective of this study was to evaluate the effectiveness of regionally-specific immunotherapy in dogs with atopic dermatitis...
January 5, 2017: BMC Veterinary Research
https://www.readbyqxmd.com/read/28052798/diagnosis-and-management-of-allergic-conjunctivitis-in-pediatric-patients
#7
William E Berger, David B Granet, Alan G Kabat
BACKGROUND: Allergic conjunctivitis (AC), although one of the most common ocular disorders in pediatric patients, is frequently overlooked, misdiagnosed, and undertreated in children. OBJECTIVE: To guide pediatric health care professionals in the optimal diagnosis and management of AC in pediatric patients. METHODS: To identify any existing best practice guidelines for the diagnosis and treatment of AC in pediatric patients, a review of the literature published between 2004 and January 2015 was conducted...
January 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28049194/early-intervention-improves-clinical-responses-to-house-dust-mite-immunotherapy-in-allergic-rhinitis-patients
#8
Shanshan Qi, Hao Chen, Nan Huang, Wenjing Li, Guanghui Liu, Yin Wang, Lintao Hu, Xiaolong Wang, Wei Zhang, Rongfei Zhu
BACKGROUND: Allergen immunotherapy (AIT) is the unique causal treatment for respiratory allergy. As AIT is expensive and of long duration, the availability of a marker predicting AIT responders is of crucial relevance. OBJECTIVE: To investigate clinical parameters correlated with effective AIT in allergic rhinitis (AR) patients. METHODS: This is a prospective, nonrandomized open study in which a total of 284 AR patients who had received house dust mite (HDM) subcutaneous AIT were enrolled from January 2011 to December 2015, and then followed up for 3 consecutive years...
2016: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28048538/th-ab-209-05-validating-hemoglobin-saturation-and-dissolved-oxygen-in-tumors-using-photoacoustic-computed-tomographic-spectroscopic-imaging
#9
J Burnett, J Sick, N Cao, B Liu, H Nakshatri, M Mendonca, K Stantz
PURPOSE: Photoacoustic computed tomographic spectroscopy (PCT-S) provides intra-tumor measurements of oxygenation with high spatial resolution (0.2mm) and temporal fidelity (1-2 minutes) without the need for exogenous agents or ionizing radiation, thus providing a unique in vivo assay to measure SaO2 and investigate acute and chronic forms of hypoxia. The goal of this study is to validate in vivo SaO2 levels within tail artery of mice and the relationship between SaO2 and pO2 within subcutaneous breast tumors using PCT-S imaging, pulse oximetry and an OxyLite probe...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28042004/the-potential-role-of-allergen-immunotherapy-in-stepping-down-asthma-treatment
#10
Pascal Demoly, Melina Makatsori, Thomas B Casale, Moises A Calderon
For patients whose asthma is controlled and who have a low risk for future exacerbations, current guidelines recommend gradually stepping down pharmacotherapy to identify the lowest dose needed to maintain control. This review article will discuss the benefits and risks of step down in asthma management and the different strategies of achieving step down with particular focus on allergen immunotherapy (AIT). A literature search was conducted to identify studies that assessed the effect of AIT on asthma step down and evaluated this and asthma control as one of the outcomes...
December 29, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28029320/pulmonary-infiltrates-in-a-patient-with-advanced-melanoma
#11
Charles A Powell
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28027502/bioactive-polysaccharide-based-ph-sensitive-polymers-for-cytoplasmic-delivery-of-antigen-and-activation-of-antigen-specific-immunity
#12
Eiji Yuba, Ayaka Yamaguchi, Yuta Yoshizaki, Atsushi Harada, Kenji Kono
For establishment of cancer immunotherapy, antigen carriers are needed which have functions not only to deliver antigen into cytosol of dendritic cells (DCs), which induces antigen-specific cellular immune responses, but also to activate DCs. We previously reported cytoplasmic delivery of antigen using liposomes modified with pH-sensitive polymers such as carboxylated poly(glycidol)s or dextran. Modification using these polymers provides stable liposomes with pH-sensitive fusogenic/membrane-disruptive ability...
December 22, 2016: Biomaterials
https://www.readbyqxmd.com/read/28018343/very-late-antigen-1-marks-functional-tumor-resident-cd8-t-cells-and-correlates-with-survival-of-melanoma-patients
#13
Timothy Murray, Silvia A Fuertes Marraco, Petra Baumgaertner, Natacha Bordry, Laurène Cagnon, Alena Donda, Pedro Romero, Grégory Verdeil, Daniel E Speiser
A major limiting factor in the success of immunotherapy is tumor infiltration by CD8(+) T cells, a process that remains poorly understood. In the present study, we characterized homing receptors expressed by human melanoma-specific CD8(+) T cells. Our data reveal that P-selectin binding and expression of the retention integrin, very late antigen (VLA)-1, by vaccine-induced T cells correlate with longer patient survival. Furthermore, we demonstrate that CD8(+)VLA-1(+) tumor-infiltrating lymphocytes (TILs) are highly enriched in melanoma metastases in diverse tissues...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27999013/pharmacological-inhibition-of-p110%C3%AE-subunit-of-pi3k-confers-protection-against-experimental-leishmaniasis
#14
Forough Khadem, Ping Jia, Zhirong Mou, Aida Feiz Barazandeh, Dong Liu, Yoav Keynan, Jude E Uzonna
OBJECTIVES: This study aimed to evaluate the immuno-prophylactic and -therapeutic effect of p110δ-specific pharmacological inhibitors (CAL-101 and IC87114), either alone or in combination with amphotericin B, against experimental cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). METHODS: Female BALB/c mice were infected intravenously with Leishmania donovani or subcutaneously with Leishmania major Prophylactic treatment was initiated 24 h prior to infection, whereas therapeutic treatments with or without amphotericin B were initiated either 1 week or 2 weeks post-infection...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27996286/safety-and-efficacy-of-ant-rush-immunotherapy-in-children
#15
Wiparat Manuyakorn, Suwat Benjaponpitak, Wasu Kamchaisatian, Cherapat Sasisakulporn, Wanlapa Jotikasthira
BACKGROUND: The Rush Immunotherapy (RIT) protocol is a valid alternative in order to reach the maintenance phase early. However, there are scarce studies in the literature that have evaluated the safety and the efficacy of an ant RIT process in children. OBJECTIVE: To evaluate the safety and the efficacy of an ant RIT protocol and to identify the risk factors for systemic reactions (SRs) during an RIT procedure in children. METHOD: A retrospective review was conducted for those children who were receiving an ant RIT procedure...
December 12, 2016: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/27989216/the-safety-of-talimogene-laherparepvec-for-the-treatment-of-advanced-melanoma
#16
Alexandra Gangi, Jonathan S Zager
Talimogene laherparepvec (T-VEC, IMLYGIC) is an oncolytic herpes virus type I used as intralesional therapy for the treatment of unresectable metastatic melanoma in a cutaneous, subcutaneous, or nodal location. Talimogene laherparepvec selectively replicates within and lyses tumor cells while producing granulocyte macrophage colony-stimulating factor (GM-CSF), which may promote an immune mediated antitumor response. Areas covered: The US Food and Drug Administration approved Talimogene laherparepvec in late 2015 following the completion of phase I, II and III trials that demonstrated safety and efficacy...
December 28, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27973543/intradermal-delivery-of-antigens-enhances-specific-igg-and-diminishes-ige-production-potential-use-for-vaccination-and-allergy-immunotherapy
#17
Takuwa Yasuda, Takehiro Ura, Masaru Taniguchi, Hisahiro Yoshida
Skin is protected by a tough but flexible multilayered barrier and is a front line for immune responses against invading particles. For many years now, skin has been a tissue where certain vaccines are injected for the prevention of infectious disease, however, the detailed mechanisms of the skin immune response are not yet well understood. Using thin and small injection needles, we carefully injected OVA into a restricted region of mouse skin, i.e., intradermal (ID), and examined the antibody response in comparison with subcutaneous (SC) injection or epicutaneous patch administration of OVA...
2016: PloS One
https://www.readbyqxmd.com/read/27957697/benefit-of-slit-and-scit-for-allergic-rhinitis-and-asthma
#18
REVIEW
Giovanni Passalacqua, Giorgio Walter Canonica, Diego Bagnasco
Allergen immunotherapy (AIT) has been in use since more than one century, when Leonard Noon experimentally proved its efficacy in hayfever (Noon, in Lancet 1:1572-3, 1911). Since then, AIT was administered only as subcutaneous injections (SCIT) until the sublingual route (SLIT) was proposed in 1986. The use of SLIT was proposed following several surveys from the USA and UK that repeatedly reported fatalities due to SCIT (Lockey et al. in J Allergy Clin Immunol 75(1): 166, 1985; Lockey et al. in J Allergy Clin Immunol 660-77, 1985; Committee on the safety of medicines...
November 2016: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/27955995/safety-and-immunogenicity-of-the-tau-vaccine-aadvac1-in-patients-with-alzheimer-s-disease-a-randomised-double-blind-placebo-controlled-phase-1-trial
#19
Petr Novak, Reinhold Schmidt, Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana, Zuzana Vince-Kazmerova, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Bengt Winblad, Michal Novak
BACKGROUND: Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against pathological tau proteins and assessed it in a phase 1 trial. METHODS: We did a first-in-man, phase 1, 12 week, randomised, double-blind, placebo-controlled study of AADvac1 with a 12 week open-label extension in patients aged 50-85 years with mild-to-moderate Alzheimer's disease at four centres in Austria...
February 2017: Lancet Neurology
https://www.readbyqxmd.com/read/27931277/american-academy-of-allergy-asthma-immunology-membership-experience-with-allergen-immunotherapy-safety-in-patients-with-specific-medical-conditions
#20
Dsire E S Larenas-Linnemann, David W Hauswirth, Christopher W Calabria, Lawrence D Sher, Matthew A Rank
BACKGROUND: Little data in the literature exist concerning patients with certain underlying medical conditions who receive allergen subcutaneous immunotherapy (SCIT). OBJECTIVE: To survey allergists' experience with SCIT in patients with medical conditions considered to impose an elevated risk for untoward outcomes. METHODS: A Web-based survey was conducted among members of the American Academy of Allergy, Asthma Immunology to query about their experience with SCIT in patients with certain medical conditions...
September 2016: Allergy and Asthma Proceedings:
keyword
keyword
54124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"